The only treatment support program specifically for patients with PPP

Strongbridge CareConnection - Patient Support Program

Services from Strongbridge CareConnection for your patients and your office

  • A dedicated case manager and Patient Access Manager are assigned to every patient
  • Patient Access Managers are available to work with healthcare providers and patients to navigate insurance coverage, including:
    • Providing education about prior authorization requirements and claims appeals
    • Helping explore coverage, co-pay assisstance options, and eligibility
    • Offering information on financial assistance programs
  • Patients receive routine calls from a licensed pharmacist once they start KEVEYIS to discuss their progress and treatment goals
  • Patients can speak with others who are living with PPP on the phone through the PPP Mentor Connect program
  • Patients receive information regarding advocacy and support group communities as well as live programs about PPP

Leslie, a patient on KEVEYIS, talks about her Patient Access Manager

PANTHERx Rare Pharmacy

PANTHERx Rare is a specialty pharmacy that prescribes KEVEYIS. It is the only way for your patient to get his or her KEVEYIS prescription.

The PANTHERx Rare program includes outreach with dedicated clinical pharmacists who will contact patients prior to shipping KEVEYIS and discuss how KEVEYIS is working for them. If patients indicate that they are experiencing adverse reactions, the pharmacist will work directly with your office to find the appropriate dose of KEVEYIS for each patient and help manage adverse reactions.

24/7 support is available to your patients through Strongbridge CareConnection.

How to Prescribe KEVEYIS for Your Patient

  1. Fill out a KEVEYIS Prescription Form
  2. Fax form to PANTHERx Rare Pharmacy at 1-844-538-1030
  3. PANTHERx Rare Pharmacy coordinates KEVEYIS shipments with your patient and provides information to the office on access and reimbursement
PANTHERx Rare Pharmacy conducts clinical outreach calls on a regular basis for KEVEYIS patients who consent. Feedback on continuing adverse reactions or attacks will be relayed to the prescriber by PANTHERx Rare Pharmacy for clinical review.
To learn more about how KEVEYIS could help your patients with PPP, click here.

*Eligible patients pay as little as $0 with a maximum annual savings of $10,000. The authorized specialty pharmacy will activate the copay card for eligible patients and apply for each prescription until the annual maximum has been reached. This card is not valid for prescriptions that may be reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other similar federal or state healthcare program, including any state pharmacy assistance program. For additional questions about the co-pay program, including eligibility, call Strongbridge CareConnection at 844-KEVEYIS (538‑3947)

EXPAND

Indication

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

Important Safety Information

Contraindications
  • Hypersensitivity to dichlorphenamide or other sulfonamides
  • Concomitant use of KEVEYIS and high-dose aspirin
  • Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
  • Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy
Warnings and Precautions

Hypersensitivity and Other Life-Threatening Reactions

  • Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
  • Pulmonary involvement can occur in isolation or as part of a systemic reaction.
  • Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

Concomitant Use of Aspirin or Other Salicylates

  • Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic acidosis, which can increase the risk of salicylate toxicity.
  • Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin.
  • Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with caution and carefully monitor in patients receiving low-dose aspirin.

Hypokalemia

  • KEVEYIS increases potassium excretion and can cause hypokalemia.
  • The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline).
  • Baseline and periodic measurements of serum potassium are recommended.
  • If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

Metabolic Acidosis

  • KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.
  • Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis.
  • Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.
  • Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.
  • If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS.

Falls

  • KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses.
  • Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.
Pregnancy and Lactation

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.

Adverse Reactions

The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.

Please see Full Prescribing Information.